The adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction

Abstract

The aGAPSS is based upon a quantitative score and could aid risk stratifying APS patients younger than 50years for the likelihood of developing coronary thrombotic events and may guide pharmacological treatment for high-risk patients.

The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort

“…It is important to clarify that this lack of association should not be considered as a rebuttal of previous data since all patients recruited to this study fulfill the criteria for APS and are strictly monitored in tertiary centers, potentially representing a sampling bias when compared to other observational cohorts. In addition, these findings are in line with the concept that aPL is a necessary but insufficient step in the development of thrombosis where a "second hit" probably pushes the haemostatic balance in favor of thrombosis by including added factors necessary for its development, such as uncontrolled traditional cardiovascular risk factors [18,19]. Among the various methods for risk stratifications, aGAPSS displays important advantages.…”

The risk of ischaemic stroke in primary antiphospholipid syndrome patients: a prospective study

“…In fact, significantly higher values of aGAPSS were found in patients with stroke. The results are in line with a very recent study from our group showing higher aGAPSS values in patients who experienced acute myocardial infarction compared to those with other thrombosis .…”

Cardiac Manifestations of Antiphospholipid Syndrome: Clinical Presentation, Role of Cardiac Imaging, and Treatment Strategies

“…44 This score was found to be useful for risk stratification in a retrospective study, involving young subjects with AMI, who had experienced at least one thrombotic event (arterial and/or venous). A modified version of aGAPSS including also diabetes, obesity, and smoking habit has been more recently proposed for risk stratification in young APS patients with AMI 45 and in subjects with aPL. 46 However, no consensus exists on the prophylactic treatment of aPL carriers who never developed vascular manifestations.…”